News & Updates

Show Multimedia Only
Pazopanib plus chemo improves response but not survival in advanced ovarian cancer

Pazopanib plus chemo improves response but not survival in advanced ovarian cancer

08 Jun 2023

Treatment with pazopanib combined with chemotherapy leads to better overall response rate (ORR) in patients with recurrent or persistent ovarian cancer but falls short of improving survival, reveals a study. In addition, the combination therapy contributes to an increase in several adverse events (AEs).

08 Jun 2023
Psychedelic drugs show promise for anxiety, depression

Psychedelic drugs show promise for anxiety, depression

08 Jun 2023

Use of psychedelic drugs appears to have some benefits in reducing anxiety and depressive symptoms among patients with cancer or other life-threatening diseases, reports a study.

08 Jun 2023
Is liposomal irinotecan superior to topotecan in relapsed small cell lung cancer?

Is liposomal irinotecan superior to topotecan in relapsed small cell lung cancer?

07 Jun 2023 byStephen Padilla

Treatment with liposomal irinotecan in adults with relapsed small cell lung cancer (SCLC) achieves similar overall survival (OS) when compared with topotecan, but the former is associated with a higher overall response rate (ORR), according to the results of RESILIENT, randomized, open-label phase III trial.

07 Jun 2023